Jyong Biotech Ltd. Ordinary Shares
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Jyong Biotech Ltd. is a science-driven biotechnology company headquartered in New Taipei City, Taiwan, specializing in the development and commercialization of innovative plant-derived drugs primarily targeting urinary system diseases. The company’s core products include MCS-2, an oral botanical drug for benign prostate hyperplasia (BPH) and lower urinary tract symptoms (LUTS); MCS-8 (PCP), a plant-derived drug candidate undergoing phase II trials for prostate cancer prevention; and IC, a preclinical-stage candidate for interstitial cystitis and bladder pain syndrome. Jyong Biotech develops these proprietary botanical drug candidates and holds multiple worldwide patents, with operations and clinical trials spanning the United States, European Union, and Asian markets, notably Taiwan, mainland China, and recently South Korea. The company was founded in 2002 and operates through five wholly owned subsidiaries. Recent major developments include the signing of a non-binding letter of intent with a leading South Korean pharmaceutical company to explore the in-licensing and commercialization of MCS-2 in the Korean market, aligning with Jyong Biotech’s strategy to expand via co-commercialization partnerships that leverage established regional sales networks and regulatory expertise. In 2025, Jyong Biotech submitted a new drug application (NDA) for MCS-2 to the U.S. FDA and reported positive Phase II clinical trial results for MCS-8 in Taiwan, demonstrating significant reductions in prostate cancer incidence among high-risk subjects. The company also received the Innovation Gold Award at the 2025 Taipei Biotech Awards for BOTRESO®, its flagship oral drug for BPH and LUTS, which has completed four Phase III clinical trials in the US and Taiwan. Jyong Biotech continues to pursue multinational Phase III trials and expand its global patent portfolio and strategic collaborations to accelerate commercial market entry. The company’s product development emphasizes innovative botanical drug technology with a strong focus on unmet medical needs in urology, supported by a proprietary research platform and a broad clinical development network. Jyong Biotech targets pharmaceutical markets in the U.S., the EU, and Asia, aiming to become a leading global supplier of plant-derived therapeutic solutions for urinary and related diseases. Its latest strategic moves underscore a focus on cross-border clinical collaboration, strategic capital deployment, and selective regional partnerships to enhance patient access and commercial scalability. Overall, Jyong Biotech Ltd. distinguishes itself as a pioneering biopharmaceutical company focused on plant-based drugs for urinary health, leveraging scientific innovation and clinical validation to penetrate major international markets while actively expanding its pipeline and commercialization footprint through strategic alliances and regulatory advancements.
Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention
Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025
Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio
Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Down 22.7% in March
Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2
Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia
Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value
Jyong Biotech Responds to Share Price and Volume Movement
Jyong Biotech Ltd.’s (NASDAQ:MENS) Lock-Up Period Will End on December 15th
Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS‑2 Market Entry
Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs
Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes
Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards
Jyong Biotech Chairwoman and CEO Set to Attend as Speaker at 2025 Global Business Forum in Taipei
Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention
Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP)
Jyong Biotech's Plant‑Based Pipeline Targets Huge Markets But Risks Remain
Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention